Cargando…

Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome

The activated phosphoinositide 3-kinase δ syndrome (APDS), also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI), is a combined immunodeficiency syndrome caused by gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Condliffe, Alison M., Chandra, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844940/ https://www.ncbi.nlm.nih.gov/pubmed/29556229 http://dx.doi.org/10.3389/fimmu.2018.00338

Ejemplares similares

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
por: Maccari, Maria Elena, et al.
Publicado: (2018)

Exhaustion of the CD8(+) T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta
por: Wentink, Marjolein W. J., et al.
Publicado: (2018)

Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
por: Bloomfield, Marketa, et al.
Publicado: (2021)

Activated phosphoinositide 3‐dinase delta syndrome (APDS): An update
por: Lougaris, Vassilios, et al.
Publicado: (2022)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
por: Yin, Zexi, et al.
Publicado: (2021)

Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus
por: Olayinka-Adefemi, Folayemi, et al.
Publicado: (2023)

Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8(+) T Cell Transcriptional Programs
por: Spinelli, Laura, et al.
Publicado: (2021)

Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells
por: Condliffe, Alison M, et al.
Publicado: (2000)

Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies
por: Puri, Kamal D., et al.
Publicado: (2012)

Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy
por: Michalovich, David, et al.
Publicado: (2018)

Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients
por: Tessarin, Giulio, et al.
Publicado: (2020)

Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases
por: Finlay, David K.
Publicado: (2012)

Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects
por: Jhamnani, Rekha D., et al.
Publicado: (2018)

Phosphoinositide 3-kinase-delta could be a biomarker for eosinophilic nasal polyps
por: Kim, Jong Seung, et al.
Publicado: (2018)

Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management
por: Jeong, Jae Seok, et al.
Publicado: (2019)

Activated phosphoinositide 3-kinase delta syndrome 2 associated with Kikuchi–Fujimoto disease: a rare Palestinian case report
por: Abulaila, Karim J., et al.
Publicado: (2023)

The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions
por: Pauls, Samantha D., et al.
Publicado: (2012)

Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency
por: Mace, Emily M.
Publicado: (2018)

Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
por: Hoellenriegel, Julia, et al.
Publicado: (2011)

Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion
por: Pham, Michele N., et al.
Publicado: (2018)

Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report
por: Zhang, Xiaojing, et al.
Publicado: (2021)

Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8(+) T Cell Survival, Differentiation, and Function
por: Cannons, Jennifer L., et al.
Publicado: (2018)

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
por: Coulter, Tanya I., et al.
Publicado: (2017)

The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes
por: Azzi, Jamil, et al.
Publicado: (2012)

Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases
por: Dornan, Gillian L., et al.
Publicado: (2018)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Pharmacological Targeting of Phosphoinositide Lipid Kinases and Phosphatases in the Immune System: Success, Disappointment, and New Opportunities
por: Blunt, Matthew D., et al.
Publicado: (2012)

Phosphoinositides and the Fate of Legionella in Phagocytes
por: Swart, A. Leoni, et al.
Publicado: (2020)

Deconvolution of bulk RNA sequencing in activated phosphoinositide 3‐kinase δ syndrome
por: Huang, Xia, et al.
Publicado: (2023)

Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival
por: He, Junming, et al.
Publicado: (2021)

Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys
por: Ewertowska, Marlena, et al.
Publicado: (2020)

DOCK2 and phosphoinositide-3 kinase δ mediate two complementary signaling pathways for CXCR5-dependent B cell migration
por: Wissmann, Stefanie, et al.
Publicado: (2022)

Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor
por: Way, Emily E., et al.
Publicado: (2016)

Occurrence of B-cell lymphomas in patients with Activated Phosphoinositide 3-Kinase δ syndrome
por: Kracker, Sven, et al.
Publicado: (2014)

Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
por: Aydin, Ebru, et al.
Publicado: (2021)

Activated PI3K delta syndrome 1 mutations cause neutrophilia in zebrafish larvae
por: Elworthy, Stone, et al.
Publicado: (2023)

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival
por: Juss, Jatinder K., et al.
Publicado: (2012)

Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival
por: Thomas, Daniel, et al.
Publicado: (2013)

Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides
por: Elich, Mila, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_59goluhjmicfucpha25ev6emf7